Vasoactive Intestinal Polypeptide
Vasoactive Intestinal Peptide | Neuropeptide
DoseGear research brief
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Endogenous vasoactive intestinal peptide.
Pulmonary, vascular, and inflammatory research through VPAC-receptor activation and cAMP-mediated signaling.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| General use | 50-100 mcg | 1-2x daily | SubQ or IV |
| Research protocols | 100-200 mcg | As directed | SubQ or IV |
Reference cycle
As prescribed for specific condition
Reference storage
Lyophilized powder: 2-8°C refrigerated; Reconstituted: use immediately (very short stability, ~2 minute half-life)
VIP as New Drug for Treatment of Primary Pulmonary Hypertension
Therapeutic Potential of VIP and VPAC2 in Type 2 Diabetes
Therapeutic Potential of VIP in Neurological Disorders
VIP Structure and Function for Therapeutic Applications
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
